Nanjing Legend Files for EU Approval of BCMA CAR-T

Nanjing Legend Biotech filed for EU approval of its BCMA CAR-T candidate in patients with multiple myeloma. In 2017, Legend stunned participants at the US ASCO meeting with the 94% complete remission rate of the CAR-T candidate. Later that year, Janssen Pharma, a division of Johnson and Johnson, paid $350 million upfront to partner the drug. Legend-Janssen is seeking European approval of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma, based on 95% overall response and 56% complete response in a Phase Ib/II study. More details.... Stock Symbol:  (NSDQ: LEGN) Share this with colleagues: // //